ES2525381T3 - Péptidos cíclicos para la regulación de canales iónicos vectoriales - Google Patents
Péptidos cíclicos para la regulación de canales iónicos vectoriales Download PDFInfo
- Publication number
- ES2525381T3 ES2525381T3 ES11705798.4T ES11705798T ES2525381T3 ES 2525381 T3 ES2525381 T3 ES 2525381T3 ES 11705798 T ES11705798 T ES 11705798T ES 2525381 T3 ES2525381 T3 ES 2525381T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- compound
- seq
- compound according
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004310 Ion Channels Human genes 0.000 title claims description 23
- 230000033228 biological regulation Effects 0.000 title claims description 15
- 102000001189 Cyclic Peptides Human genes 0.000 title description 3
- 108010069514 Cyclic Peptides Proteins 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- 150000001413 amino acids Chemical group 0.000 claims abstract description 79
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 40
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 33
- 125000003277 amino group Chemical group 0.000 claims abstract description 26
- 238000006798 ring closing metathesis reaction Methods 0.000 claims abstract description 17
- -1 Cyclic organic compound Chemical class 0.000 claims abstract description 14
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 11
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 10
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960003104 ornithine Drugs 0.000 claims abstract description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 66
- 239000004471 Glycine Substances 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 20
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 18
- 210000004072 lung Anatomy 0.000 claims description 15
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 12
- 208000005333 pulmonary edema Diseases 0.000 claims description 12
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 11
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims description 8
- 206010030113 Oedema Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 6
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229960002684 aminocaproic acid Drugs 0.000 claims description 6
- 231100000516 lung damage Toxicity 0.000 claims description 6
- 230000004199 lung function Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 102100036956 Chromatin target of PRMT1 protein Human genes 0.000 claims description 2
- 101710197132 Chromatin target of PRMT1 protein Proteins 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 235000019568 aromas Nutrition 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 28
- 229910052799 carbon Inorganic materials 0.000 description 28
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 239000012528 membrane Substances 0.000 description 21
- 108090000862 Ion Channels Proteins 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 13
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000010532 solid phase synthesis reaction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 3
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000003456 pulmonary alveoli Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- 102000010637 Aquaporins Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- HBZVNWNSRNTWPS-UHFFFAOYSA-N 6-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(O)C2=CC(N)=CC=C21 HBZVNWNSRNTWPS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- XWIJIXWOZCRYEL-UHFFFAOYSA-M potassium;methanesulfonate Chemical compound [K+].CS([O-])(=O)=O XWIJIXWOZCRYEL-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000036412 respiratory physiology Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT412010 | 2010-01-14 | ||
| AT0004110A AT509267A1 (de) | 2010-01-14 | 2010-01-14 | Organische verbindungen zur regulierung von vektoriellen ionenkanälen |
| PCT/AT2011/000014 WO2011085423A1 (de) | 2010-01-14 | 2011-01-12 | Zyklische peptide zur regulierung von vektoriellen ionenkanälen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2525381T3 true ES2525381T3 (es) | 2014-12-23 |
Family
ID=43970939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11705798.4T Active ES2525381T3 (es) | 2010-01-14 | 2011-01-12 | Péptidos cíclicos para la regulación de canales iónicos vectoriales |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8754049B2 (https=) |
| EP (1) | EP2523968B1 (https=) |
| JP (1) | JP5771220B2 (https=) |
| KR (1) | KR101865420B1 (https=) |
| CN (1) | CN102770442B (https=) |
| AT (1) | AT509267A1 (https=) |
| AU (1) | AU2011206907B2 (https=) |
| BR (1) | BR112012017093A2 (https=) |
| CA (1) | CA2785185C (https=) |
| DK (1) | DK2523968T3 (https=) |
| ES (1) | ES2525381T3 (https=) |
| IL (1) | IL220924B (https=) |
| NZ (1) | NZ600818A (https=) |
| PL (1) | PL2523968T3 (https=) |
| RU (1) | RU2538597C2 (https=) |
| WO (1) | WO2011085423A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
| KR102217476B1 (ko) * | 2013-04-23 | 2021-02-19 | 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 | 식 ｘ₁－ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ－ｘ₂의 고리 펩티드를 함유하는 동결건조물 |
| US20160143266A1 (en) * | 2013-04-23 | 2016-05-26 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| US12004506B2 (en) | 2013-04-23 | 2024-06-11 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| CA2939635A1 (en) * | 2014-03-04 | 2015-09-11 | Apeptico Forschung Und Entwicklung Gmbh | Attenuation of intrapulmonary inflammation |
| IL258067B (en) * | 2015-09-14 | 2022-08-01 | Apeptico Forschung & Entwicklung Gmbh | Circular protein for the treatment of pha type 1b |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968753A (en) * | 1994-06-14 | 1999-10-19 | Nexell Therapeutics, Inc. | Positive and positive/negative cell selection mediated by peptide release |
| EP1264599B1 (en) | 1998-08-14 | 2007-09-26 | Rudolf Lucas | TNF-derived peptides for use in treating oedema |
| FR2839514A1 (fr) * | 2002-05-07 | 2003-11-14 | Centre Nat Rech Scient | Nouveaux peptides cycliques, leur utilisation comme agents anti-microbiens |
| CA2575513C (en) * | 2004-08-06 | 2014-09-16 | Altana Pharma Ag | Composition comprising a pulmonary surfactant and a tnf-derived peptide |
| CN101007791A (zh) * | 2007-01-12 | 2007-08-01 | 东华大学 | 一种氨基酸联苯化合物 |
| CN101003520A (zh) * | 2007-01-12 | 2007-07-25 | 陈志龙 | 一种缬氨酸丁酰联苯化合物 |
| EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
| AT506151B1 (de) * | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Fusionsprotein |
| AT506150B1 (de) * | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Zyklisches und cystein-freies peptid |
| CN101298432B (zh) * | 2008-05-30 | 2010-12-22 | 广州市星业科技发展有限公司 | L-吡咯烷酮羧酸钠的制备方法 |
| EP2296685B1 (en) * | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AT507953B1 (de) * | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
| PL2397151T3 (pl) * | 2010-06-21 | 2015-10-30 | Apeptico Forschung & Entwicklung Gmbh | Leczenie powikłań naczyniowych cukrzycy |
-
2010
- 2010-01-14 AT AT0004110A patent/AT509267A1/de not_active Application Discontinuation
-
2011
- 2011-01-12 PL PL11705798T patent/PL2523968T3/pl unknown
- 2011-01-12 US US13/522,204 patent/US8754049B2/en active Active
- 2011-01-12 CN CN201180005765.9A patent/CN102770442B/zh active Active
- 2011-01-12 DK DK11705798.4T patent/DK2523968T3/da active
- 2011-01-12 EP EP11705798.4A patent/EP2523968B1/de active Active
- 2011-01-12 WO PCT/AT2011/000014 patent/WO2011085423A1/de not_active Ceased
- 2011-01-12 NZ NZ600818A patent/NZ600818A/en not_active IP Right Cessation
- 2011-01-12 AU AU2011206907A patent/AU2011206907B2/en not_active Ceased
- 2011-01-12 BR BR112012017093A patent/BR112012017093A2/pt not_active IP Right Cessation
- 2011-01-12 ES ES11705798.4T patent/ES2525381T3/es active Active
- 2011-01-12 JP JP2012548306A patent/JP5771220B2/ja active Active
- 2011-01-12 RU RU2012134322/04A patent/RU2538597C2/ru not_active IP Right Cessation
- 2011-01-12 CA CA2785185A patent/CA2785185C/en active Active
- 2011-01-12 KR KR1020127018445A patent/KR101865420B1/ko active Active
-
2012
- 2012-07-12 IL IL220924A patent/IL220924B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AT509267A1 (de) | 2011-07-15 |
| DK2523968T3 (da) | 2014-11-03 |
| RU2538597C2 (ru) | 2015-01-10 |
| KR20120134100A (ko) | 2012-12-11 |
| KR101865420B1 (ko) | 2018-07-13 |
| IL220924B (en) | 2018-04-30 |
| AU2011206907B2 (en) | 2016-06-02 |
| PL2523968T3 (pl) | 2015-03-31 |
| NZ600818A (en) | 2014-02-28 |
| JP2013517224A (ja) | 2013-05-16 |
| JP5771220B2 (ja) | 2015-08-26 |
| AU2011206907A1 (en) | 2012-06-21 |
| HK1174341A1 (en) | 2013-06-07 |
| CA2785185C (en) | 2019-02-19 |
| EP2523968B1 (de) | 2014-09-10 |
| US8754049B2 (en) | 2014-06-17 |
| CA2785185A1 (en) | 2011-07-21 |
| CN102770442A (zh) | 2012-11-07 |
| WO2011085423A1 (de) | 2011-07-21 |
| RU2012134322A (ru) | 2014-02-20 |
| EP2523968A1 (de) | 2012-11-21 |
| US20130072444A1 (en) | 2013-03-21 |
| BR112012017093A2 (pt) | 2016-11-29 |
| CN102770442B (zh) | 2015-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525381T3 (es) | Péptidos cíclicos para la regulación de canales iónicos vectoriales | |
| US11639368B2 (en) | Method for preventing and treating hyperpermeability | |
| ES2279522T3 (es) | Preparaciones liofilizadas de hgf. | |
| ES2602197T3 (es) | Composición farmacéutica para el tratamiento de la forma pulmonar del mal de montaña causada por falta de oxígeno y presión atmosférica reducida | |
| ES2952519T3 (es) | Polipéptidos cíclicos, su procedimiento de obtención y su aplicación en terapéutica | |
| ES2398758T3 (es) | Proteína ciclica libre de cisteína | |
| ES2876404T3 (es) | Liofilizado que contiene un péptido cíclico de fórmula X1-GQRETPEGAEAKPWY-X2 para el tratamiento de edemas pulmonares | |
| US20080139462A1 (en) | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions | |
| CN117720661A (zh) | 一种具有神经保护功效的自组装硫环肽及其制备方法和应用 | |
| ES2400316T3 (es) | Proteína inversa | |
| HK1174341B (en) | Cyclic peptides for regulation of vectorial ion channels | |
| HK1142342B (en) | Cyclic, cystein-free protein | |
| HK1146905B (en) | Reverse protein |